A detailed history of Jane Street Group, LLC transactions in Chimerix Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 16,473 shares of CMRX stock, worth $15,978. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,473
Previous 17,796 7.43%
Holding current value
$15,978
Previous $18,000 22.22%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.87 - $1.05 $1,151 - $1,389
-1,323 Reduced 7.43%
16,473 $14,000
Q1 2024

May 15, 2024

SELL
$0.91 - $1.26 $161,532 - $223,660
-177,508 Reduced 90.89%
17,796 $18,000
Q4 2023

Feb 14, 2024

BUY
$0.9 - $1.06 $135,906 - $160,067
151,007 Added 340.9%
195,304 $187,000
Q3 2023

Nov 14, 2023

BUY
$0.94 - $1.23 $9,609 - $12,574
10,223 Added 30.0%
44,297 $42,000
Q2 2023

Aug 14, 2023

BUY
$1.1 - $1.54 $37,481 - $52,473
34,074 New
34,074 $41,000
Q4 2022

Feb 14, 2023

BUY
$1.67 - $2.35 $22,459 - $31,605
13,449 Added 16.77%
93,638 $174,000
Q3 2022

Nov 14, 2022

BUY
$1.81 - $2.76 $145,142 - $221,321
80,189 New
80,189 $154,000
Q2 2022

Aug 16, 2022

SELL
$1.34 - $5.34 $55,588 - $221,524
-41,484 Closed
0 $0
Q1 2022

May 17, 2022

SELL
$4.58 - $6.8 $98,593 - $146,383
-21,527 Reduced 34.16%
41,484 $190,000
Q4 2021

Feb 15, 2022

BUY
$5.23 - $7.18 $275,720 - $378,522
52,719 Added 512.23%
63,011 $405,000
Q3 2021

Nov 16, 2021

BUY
$5.94 - $8.75 $61,134 - $90,055
10,292 New
10,292 $64,000
Q1 2021

May 18, 2021

SELL
$4.76 - $11.25 $86,265 - $203,883
-18,123 Closed
0 $0
Q4 2020

Feb 17, 2021

BUY
$2.43 - $5.42 $44,038 - $98,226
18,123 New
18,123 $88,000
Q3 2020

Nov 17, 2020

SELL
$2.3 - $3.72 $103,913 - $168,069
-45,180 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$1.33 - $3.63 $60,089 - $164,003
45,180 New
45,180 $140,000

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.